EGFR and neoplasm: Among all NSCLC patients, about 25% are estimated to harbor “activating mutations” in sequences encoding the epidermal growth factor receptor (EGFR) that causes a constitutive activation of the EGFR signaling pathway and thus provides tumor cells with an increased abnormal growth advantage.